A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)

  • Breast Cancer
Trial Status:

Active, not recruiting

This trial runs in
Cities
  • Almada
  • Ancona
  • Aviano
  • Bari
  • Barletta
  • Brescia
  • București
  • Burgas
  • Camposampiero
  • Catania
  • Cluj-Napoca
  • Coimbra
  • Cona
  • Craiova
  • Florence
  • Graz
  • Klagenfurt am Wörthersee
  • Latina
  • Legnago
  • Leoben
  • Linz
  • Lisboa
  • Loures
  • Lucca
  • Modena
  • Palermo
  • Perugia
  • Plovdiv
  • Ponderano
  • Porto
  • Ried im Innkreis
  • Ruse
  • Sofia
  • Sora
  • Stara Zagora
  • Timișoara
  • Varna
  • Verona
  • Villach
  • Viterbo
  • Vratsa
  • Wien
  • wiener-neustadt
  • София
Trial Identifier:

NCT02913456 MO39146

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This disease registry is a prospective, multicenter non-interventional study designed to observe anti-cancer treatment regimens and clinical outcomes in participants with HER2-positive unresectable LA/mBC. Diagnosis of unresectable LA or mBC can be up to 6 months old prior to registry enrollment.

      Hoffmann-La Roche Sponsor
      NCT02913456 , MO39146 Trial Identifier
      Breast Cancer Condition
      Official Title

      A European Disease Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
        - Initially diagnosed with HER2-positive unresectable LA/mBC no more than 6 months prior to enrollment, although they can have received anti-cancer treatment during that time
      Exclusion Criteria
        - Not applicable

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now